LeMaitre Vascular, Inc. Share Price BOERSE MUENCHEN

Equities

LHU

US5255582018

Advanced Medical Equipment & Technology

Market Closed - BOERSE MUENCHEN 20:43:51 14/06/2024 BST 5-day change 1st Jan Change
73.5 EUR +1.38% Intraday chart for LeMaitre Vascular, Inc. +1.38% +40.00%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 215M 201M 16.96B Sales 2025 * 231M 216M 18.24B Capitalization 1.8B 1.68B 142B
Net income 2024 * 40M 37.37M 3.15B Net income 2025 * 44M 41.11M 3.47B EV / Sales 2024 * 8.36 x
Net cash position 2024 * - 0 0 Net cash position 2025 * - 0 0 EV / Sales 2025 * 7.77 x
P/E ratio 2024 *
45.2 x
P/E ratio 2025 *
41 x
Employees -
Yield 2024 *
0.8%
Yield 2025 *
0.82%
Free-Float 84.65%
More Fundamentals * Assessed data
Dynamic Chart
1 week+1.38%
Current month+0.68%
1 month+2.80%
3 months+19.51%
6 months+42.72%
Current year+40.00%
More quotes
1 week
72.50
Extreme 72.5
73.50
1 month
70.50
Extreme 70.5
75.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 59 31/05/92
President 60 31/12/96
Director of Finance/CFO 59 31/12/04
Members of the board TitleAgeSince
Director/Board Member 58 08/04/14
Director of Finance/CFO 59 31/12/04
Director/Board Member 76 16/09/08
More insiders
Date Price Change
14/06/24 73.5 +1.38%
13/06/24 72.5 0.00%
12/06/24 72.5 0.00%
11/06/24 72.5 0.00%
10/06/24 72.5 0.00%

Real-time BOERSE MUENCHEN, June 14, 2024 at 08:43 pm

More quotes
LeMaitre Vascular, Inc. is a provider of devices, implants, and services for the treatment of peripheral vascular disease. The Company develops, manufactures, and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. Its portfolio of product lines is primarily used to treat vascular disease, of which most are used in open vascular surgery and dialysis access. It also offers human vascular and cardiac tissue cryopreservation services. Its principal product lines include anastomotic clips, biologic vascular and dialysis grafts, biologic vascular and cardiac patches, carotid shunts, embolectomy catheters, occlusion catheters, radiopaque marking tape, synthetic vascular and dialysis grafts, and valvulotomes. The Company’s principal biologic offerings include vascular and cardiac patches as well as vascular and dialysis grafts. The Company sells its products and services primarily through a direct sales force.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
80.09 USD
Average target price
81.25 USD
Spread / Average Target
+1.45%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW